Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case: Amitav Hajra, University of Michigan: Based upon a report from the University of Michigan, information obtained by the Office of Research Integrity (ORI) during its oversight review, and Mr. Hajra\'s own admission, ORI found that Mr. Hajra, former graduate student, University of Michigan, engaged in scientific misconduct by falsifying and fabricating research data in five published research papers, two published review articles, one submitted but unpublished paper, in his doctoral dissertation, and in a submission to the GenBank computer data base. Mr. Hajra\'s doctoral training and research was supported by two Public Health Service (PHS) grants, and his experiments were conducted at and submitted for publication from the National Center for Human Genome Research, National Institutes of Health (NIH). Specifically, Mr. Hajra fabricated and falsified original research in the following publications:   • Hajra, A., Collins, F.S. \`\`Structure of the leukemia- associated human CBFB gene.\'\' Genomics 26(3):571-579, 1995 (Retracted in Genomics 38(1):107, 1996);   • Hajra, A., Liu, P.P., Speck, N.A., Collins, F.S. \`\`Overexpression of core-binding factor α (CBFα) reverses cellular transformation by the CBFβ-smooth muscle myosin heavy chain chimeric oncoprotein.\'\' Molecular and Cellular Biology 15(9):4980-4989, 1995;   • Hajra, A., Liu, P.P., Wang, Q., Kelley, C.A., Stacy, T., Adelstein, R.S., Speck, N.A., and Collins, F.S. \`\`The leukemic core binding factor β-smooth muscle myosin heavy chain (CBFβ-SMMHC) chimeric protein requires both CBFβ and myosin heavy chain domains for transformation of NIH 3T3 cells.\'\' Proc. Natl. Acad. Sci. USA 92(6):1926-1930, 1995;   • Wijmenga, C., Gregory, P.E., Hajra, A., Schrock, E., Ried, T., Eils, R., Liu, P.P., and Collins, F.S. \`\`Core binding factor β-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.\'\' Proc. Natl. Acad. Sci. USA 93(4):1630- 1635, 1996; and   • Liu, P.P., Wijmenga, C., Hajra, A., Blake, T.B., Kelley, C.A., Adelstein, R.S., Bagg, A., Rector, J., Cotelingham, J., Willman, C.L., and Collins, F.S. \`\`Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.\'\' Genes, Chromosomes, and Cancer 16:77-87, 1996 (Erratum in Genes, Chromosomes, and Cancer 18(1):71, 1997). Mr. Hajra included fabricated and falsified data in the following review articles:   • Hajra, A., Liu, P.P., and Collins, F.S. \`\`Transforming properties of the leukemic Inv(16) fusion gene CBFB-MYH11.\'\' In Molecular Aspects of Myeloid Stem Cell Development in Current Topics in Microbiology and Immunology (L. Wolff and A.S. Perkins, Eds.) 211:289- 298, 1996 (Review). Berlin and New York: Springer-Verlag; and   • Liu, P.P., Hajra, A., Wijmenga, C., and Collins, F.S. \`\`Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.\'\' Blood 85:2289-2302, 1995 (Review). Mr. Hajra submitted a fabricated nucleotide sequence in computer data base entry U22149, \`\`Human leukemia-associated core binding factor subunit CBFbeta (CBFB) gene, promoter region and partial CDs.\'\' GenBank (NCBI, NLM, NIH), March 3, 1995 (withdrawn). He also fabricated the majority of data reported in his dissertation (Hajra, A. \`\`Transformation properties of the leukemic CBFβ-SMMHC chimeric protein.\'\' Dissertation, University of Michigan, Ann Arbor, MI, 1995), and he fabricated and falsified original research data in a submitted but unpublished manuscript (Hajra, A., Liu, P.P., Itoh, K., Kelley, C.A., Speck, N.A., Adelstein, R.S., and Collins, F.S. \`\`Myosin heavy chain properties necessary for cellular transformation by the leukemic CBFβ-SMMHC oncoprotein,\'\' submitted for publication to Oncogene on November 29, 1995, and on May 15, 1996). Mr. Hajra has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the four (4) year period beginning July 7, 1997, to exclude himself from: (1) Contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations); (2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Mr. Hajra agreed to request or cooperate in requesting the retraction or correction of those research publications that have not already been corrected or retracted. He also agreed to notify the relevant editors of the affected review articles that the articles cannot be relied upon.
